The Pragmatic Shift in Drug Safety
2026 marks a turning point for pharmacovigilance - not because AI arrived, but because the industry finally stopped pretending it would solve everything on its own.
How long can a compliance function scale on human bandwidth alone, when the data volume doubles faster than headcount ever could?
As a Head of PV, I reached a straightforward conclusion: manual processing is a compliance risk, not just an inefficiency. Safety data grows at 15–20% annually. The global VigiBase database has surpassed 40 million reports. Traditional human-led processing simply cannot keep pace with that volume, and the gap between capacity and obligation widens every year. According to Deloitte's 2026 AI Insights, early adopters are already projecting a 20% reduction in operational costs by redirecting focus from manual entry to AI-driven oversight.
What We Were Promised - And What We Actually Needed
When AI entered the pharmacovigilance conversation, it arrived with considerable force and considerable overstatement. Vendor presentations described end-to-end automation, self-learning signal detection, and autonomous case processing requiring only supervisory oversight. For departments under mounting pressure, it was a difficult proposition to scrutinise critically. Many companies committed to pilot programmes before robust implementation frameworks existed.
The disappointment that followed was structural, not technological.
First-generation AI systems frequently operated without auditable reasoning chains - producing outputs without explaining the basis for them. In a GxP-regulated environment, that is a regulatory incompatibility, not a technical inconvenience. Every applicable guidance on AI in the medicines lifecycle requires that decisions affecting patient safety be traceable and explainable. A system that cannot satisfy this requirement cannot function as a compliance asset.
The validation burden was also systematically underestimated. Deploying AI in a regulated PV environment requires IQ/ OQ/PQ protocols, ongoing performance monitoring, and change control infrastructure that most vendor timelines had not accounted for. The result: persistent gap between commercial promises and operational reality, one that erodes confidence and stalls adoption across the industry.
The practical lesson from this period was a conceptual one: AI is a precision instrument, not an autonomous operator.
And if the first wave of AI pilots failed, does that mean the technology was wrong - or that the expectations were?
Pharmacovigilance spans a spectrum from structured, reproducible operations - duplicate detection, format validation, narrative templating - to complex clinical judgements requiring medical expertise, contextual reasoning, and regulatory experience. The former represents a legitimate and high-value domain for AI applications. The latter remains the professional responsibility of qualified PV specialists.
Organisations that made this distinction early - defining AI's role precisely, validating it rigorously, and maintaining clear human accountability - are today achieving measurable operational outcomes.
What Actually Works: Three Targeted Applications
The gap between AI's theoretical potential and its practical value closes considerably when implementation is scoped with precision. In our department, AI has been deployed as a targeted intervention in three specific workflow areas — each chosen because it combines high volume, structural reproducibility, and a clear boundary where human expertise takes over.
Literature Monitoring
Systematic literature monitoring remains one of the most resource-intensive obligations in pharmacovigilance, particularly as publication volumes continue to grow. AI has changed how our team approaches this task at every stage.
At the outset, AI assists in generating and refining search strategies - producing query structures across multiple databases that would previously require significant specialist time to construct and validate. At the screening stage, preliminary relevance assessment filters incoming articles before they reach a human reviewer, ensuring that specialists focus on publications with genuine safety relevance rather than processing the full retrieval set manually. For articles that proceed to review, AI-generated summaries provide an immediate understanding of scope, methodology, and key findings, allowing the reviewer to assess relevance and priority without reading each paper in full before making that determination.
The result is automated literature monitoring that makes the human-led process substantially more efficient.
Intelligent Case Processing
Individual Case Safety Report processing is, by volume, one of the most demanding operational functions in any PV department. Three AI applications have demonstrated consistent practical value in our case handling workflow.
1. Narrative generation. AI produces structured draft case narratives from source data, which medical reviewers then assess, refine, and approve. The specialist's role shifts from transcription to critical review, a more appropriate use of clinical expertise.
2. Adverse reaction report mapping. AI assists in structuring the key data elements of a report, reducing the risk of omission and improving consistency across cases.
3. Translation support. In a global safety database environment, incoming reports arrive in multiple languages. AI-assisted translation accelerates initial processing without compromising the accuracy review that follows.
Across all three applications, the principle is consistent: AI handles the structural and linguistic groundwork; the qualified specialist exercises judgement on the output.
Signal Detection and Management
Signal detection presents a specific challenge that is as much about attention management as analytical capacity. As report volumes grow, the risk is not that signals go undetected by algorithms; it is that they go unreviewed by people overwhelmed by noise.
Automated deduplication addresses this directly. By systematically identifying and filtering duplicate reports, the system ensures that signal management activity concentrates on validated, novel safety information rather than distributing effort across redundant entries. The workflow becomes linear rather than iterative — specialists move through a structured, prioritised queue rather than navigating an undifferentiated volume of incoming data. The platform creates the conditions under which signal decisions can be made rigorously and consistently.
How Not to Buy AI: A Strategic Framework
The most consequential decisions in AI adoption are made before any software is selected. Companies that approach procurement by evaluating platforms first—comparing features, requesting demos, assessing pricing—routinely arrive at technically capable solutions that fail operationally, because the underlying strategic questions were never answered.
Strategy before software. Before evaluating any AI solution, a PV department must define with precision specific processes being targeted, measurable outcomes expected, performance assessment approach, and where human oversight is non-negotiable. Without this framework, software selection becomes a procurement exercise rather than a strategic one.
The right question is not "What can this AI do?" It is "What specific problem in our workflow does this solve, and how will we know it is solving it?"
The risk calculus. A common source of institutional hesitation is the fear of AI errors--the possibility that an automated system will misclassify a case, miss a relevant article, or generate an inaccurate narrative. This concern is legitimate and must be addressed through validation. But it must be placed in a proper context.
The liability of human oversight at scale is equally real, and far less frequently examined. A PV team processing hundreds of cases under time pressure, across multiple time zones with finite cognitive resources, does not operate in a zero-error environment. Fatigue, inconsistency, and attention degradation are systematic risks in any high-volume manual process. A strategic AI framework must weigh both sides of this equation honestly.
The issue is not the one an AI system makes under controlled conditions with audit trails and performance monitoring, but one a qualified specialist makes at 6 PM on a Friday, processing the hundredth case of the week, without the cognitive resources they had for the first case received that morning. That mistake is real, systematic, and in a high-volume PV operation, structurally inevitable without support.
AI does not eliminate errors. It changes where error occurs, reduces its frequency in high-volume routine tasks, and critically makes it visible and auditable in ways that human error rarely is.
Validation as a continuous commitment: AI implementation in a regulated pharmacovigilance environment does not end at go-live. Computer System Validation requires documented protocols, defined acceptance criteria, and evidence of consistent performance. Beyond initial validation, ongoing maintenance—monitoring for model drift, managing updates within change control, and revalidating where necessary—represents a sustained operational commitment.
Companies that treat validation as a one-time deployment requirement will find their AI systems gradually diverging from the performance standards on which regulatory acceptance was based. Governance must be resourced appropriately from the outset.
Overcoming Implementation Barriers
Navigating GxP Requirements
AI systems in a pharmacovigilance context are subject to the same regulatory expectations as any other computerised system in a GxP environment. Before any AI tool touches a safety-relevant process, it must be qualified and validated in accordance with applicable guidance - including EMA's reflection paper on AI in the medicines lifecycle, the EU AI Act, FDA's framework for AI-based software, and established CSV principles under GAMP 5.
In practice, this requires a structured approach: defining the intended use and risk classification of the system, executing documented acceptance criteria, and establishing ongoing monitoring to detect performance degradation. The validation package must demonstrate not only that the system performs as intended at implementation, but that its outputs remain fit for purpose as data patterns evolve.
AI validation is a living process, not a project milestone. That is the operational mindset that sustains compliant deployment.
Preparing the PV Team
The organisational dimension of AI implementation is frequently underestimated, and in my experience, it is where the most significant implementation risk resides. Technology can be validated and deployed; people require a different kind of preparation.
The shift AI introduces is a fundamental change in what the pharmacovigilance team is asked to do. Professionals who have developed expertise in data entry, narrative writing, and case formatting will find that AI progressively assumes those tasks. What remains and what expands is the work of critical review, medical interpretation, quality oversight, and regulatory judgement.
This professional transition requires investment in training: not only in how to use AI tools, but in developing the analytical and evaluative competencies that become central to the role. It requires transparent communication about how workflows will change and what new expectations look like. And it requires leadership that frames AI adoption as an elevation of professional responsibility - moving the PV specialist from data processor to data analyst, from administrator to expert.
Organisations that neglect this transition risk a subtler failure than a failed implementation: a technically functional AI deployment operating within a team that does not trust it, does not engage with it critically, and defaults to manual workarounds whenever possible. The technology is only as effective as the professionals working alongside it.
The Future Role of the PV Professional
The question that surfaces most reliably in any serious conversation about AI in pharmacovigilance is whether the technology will replace the people who do this work. The answer, examined honestly, is no - and the reasons are instructive.
The QPPV carries a responsibility that is regulatory, medical, and ethical in equal measure. Benefit-risk characterisation, signal interpretation, regulatory dialogue, and the exercise of scientific judgement under uncertainty are not tasks that decompose into pattern recognition. They require contextual reasoning, professional accountability, and clinical insight built over years of practice. AI can inform that judgement. It cannot substitute for it.
What AI genuinely offers is the return of time and cognitive capacity that has, for too long, been consumed by volumedriven administrative work. A specialist who is no longer manually processing the hundredth case narrative of the week is available for the complex medical assessment that actually requires their expertise. This is a structural reorientation of what pharmacovigilance work looks like at its best - not a marginal efficiency gain.
AI implemented with precision- -scoped correctly, validated rigorously, governed continuously--does not diminish the pharmacovigilance profession. It defines a clearer, more valuable version of it. The future of drug safety is a working model in which each does what it does best: AI handling the reproducible at scale, and the PV professional exercising the irreplaceable judgement that patient safety ultimately depends on.
